Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function?

Breast

Volumn 22, Issue 4, 2013, Pages 482-487

  Lu, Christine Y ^a   Srasuebkul, Preeyaporn ^b,d   Drew, Anna K ^b   Chen, Katie ^c   Ward, Robyn L ^b   Pearson, Sallie Anne ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Breast cancer; Cardiotoxicity; Data linkage; Drug safety; Trastuzumab

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGE; AGED; ARTICLE; AUSTRALIA; BREAST METASTASIS; CANCER PATIENT; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HEART FUNCTION TEST; HUMAN; MAJOR CLINICAL STUDY; PATIENT ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 84879784842     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.04.011     Document Type: Article

References (33)

1. GLOBOCAN Breast cancer incidence and mortality worldwide in 2008 2008, [accessed 05.09.12]. http://globocan.iarc.fr/factsheets/cancers/breast.asp.
2. American Cancer Society. Breast cancer facts & figures 2011-2012. [accessed 05.09.12]. http://www.cancer.org/Research/CancerFactsFigures/BreastCancerFactsFigures/breast-cancer-facts-and-figures-2011-2012.
3. Verma S., Ewer M.S. Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?. Ann Oncol 2011, 22:1011-1018.
4. Albini A., Pennesi G., Donatelli F., Cammarota R., De Flora S., Noonan D.M. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. JNatl Cancer Inst 2010, 102:14-25.
5. Ewer M.S., Lenihan D.J. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?. JClin Oncol 2008, 26:1201-1203.
6. Stebbing J., Jones A., Barrett-Lee P. Cardiotoxicity and anthracyclines. Breast Cancer Res Treat 2008, 107:451-453.
7. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEngl J Med 2001, 344:783-792.
8. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEngl J Med 2005, 353:1659-1672.
9. Tan-Chiu E., Yothers G., Romond E., Geyer C., Ewer M., Keefe D., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. JClin Oncol 2005, 23:7811-7819.
10. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Pawlicki M., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (A-CT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005, 94(Suppl. 1).
11. Smith I., Procter M., Gelber R.D., Guillaume S., Feyereislova A., Dowsett M., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
12. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., et al. Adjuvant trastuzumab in HER2-positive breast cancer. NEngl J Med 2011, 365:1273-1283.
13. Mackey J.R., Clemons M., Cote M.A., Delgado D., Dent S., Paterson A., et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 2008, 15:24-35.
14. Ewer S.M., Ewer M.S. Cardiotoxicity profile of trastuzumab. Drug Saf 2008, 31:459-467.
15. Guarneri V., Lenihan D.J., Valero V., Durand J., Broglio K., Hess K., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. JClin Oncol 2006, 24:4107-4115.
16. Serrano C., Cortes J., De Mattos-Arruda L., Bellet M., Gomez P., Saura C., et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 2012, 23:897-902.
17. Tarantini L., Cioffi G., Gori S., Tuccia F., Boccardi L., Bovelli D., et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. JCard Fail 2012, 18:113-119.
18. Aiello Bowles E.J., Wellman R., Feigelson S., Onitilo A., Freedman A., Delate T., et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. JNatl Cancer Inst 2012 Sep 5, 104(17):1293-1305.
19. Pearson S.A., Ringland C.L., Ward R.L. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia - monitoring the effect of an expensive medicine access program. JClin Oncol 2007, 25:3688-3693.
20. Extra J.M., Antoine E.C., Vincent-Salomon A., Delozier T., Kerbrat P., Bethune-Volters A., et al. Efficacy of trastuzumab inroutine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 2010, 15:799-809.
21. Subar M., Lin W., Chen W., Pittman D.G. Lack of uniformity in cardiac assessment during trastuzumab therapy. Breast J 2011, 17:383-390.
22. Allen L.A., Yood M.U., Wagner E.H., Aiello Bowles E.J., Pardee R., Wellman R., et al. Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer. Med Care 2012 May 25, [Epub ahead of print].
23. UK National Institute for Health and Clinical Excellence Early and locally advanced breast cancer: diagnosis and treatment (clinical guideline 80) 2009, London.
24. Australian National Breast Cancer Centre Recommendations for use of trastuzumab (Herceptin) for the treatment of HER2-positive breast cancer 2007, Australian National Breast Cancer Centre, Sydney.
25. Jones A.L., Barlow M., Barrett-Lee P.J., Canney P., Gilmour I., Robb S., et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009, 100:684-692.
26. Hunt S.A., Abraham W.T., Chin M.H., Feldman A., Francis G., Ganiats T., et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. JAm Coll Cardiol 2009, 53:e1-e90.
27. Lu C.Y., Srasuebkul P., Drew A.K., Ward R.L., Pearson S.A. Positive spillover effects of prescribing requirements: increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer. Intern Med J 2012 Nov, 42(11):1229-1235.
28. Australian Bureau of Statistics SEIFA: socio-economic indexes for areas 2006, Available at:, [accessed 18.08.10]. http://www.abs.gov.au.
29. Sloan K.L., Sales A.E., Liu C.F., Fishman P., Nichol P., Suzuki N., et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Med Care 2003, 41:761-774.
30. Lu C.Y., Barratt J., Vitry A., Roughead E. Charlson and Rx-risk comorbidity indices were predictive of mortality in the Australian health care setting. JClin Epidemiol 2011, 64:223-228.
31. Famoye F., Singh K.P. Zero-inflated generalized Poisson regression model with an application to domestic violence data. JData Sci 2006, 4:117-130.
32. Tuma R.S. Trastuzumab trials steal show at ASCO meeting. JNatl Cancer Inst 2005, 97:870-871.
33. Ewer M.S., Vooletich M.T., Durand J.B., Woods M., Davis J., Valero V., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. JClin Oncol 2005, 23:7820-7826.